利格列汀杂质对照品结构确证-深圳欧翔生物科技有限公司

产品分类

您的位置：首页 > 产品中心 > 药物杂质对照品 > 杂质对照品 > 利格列汀杂质对照品结构确证

产品中心

: 产品名称： 利格列汀杂质对照品结构确证

产品型号：

更新时间： 2021-02-05

描述：利格列汀杂质对照品结构确证
图谱证书齐全，纯度高，质量保证，价格优惠，可接定制。
25mg/50mg/100mg等多种规格可选。

在线询价 >联系我们 >

产品介绍

品牌	自营品牌	供货周期	现货
应用领域	医疗卫生,环保,食品,化工,生物产业

利格列汀杂质对照品结构确证

随货提供：所有杂质对照品均随货提供HPLC，NMR，MS图谱及CoA证书。

杂质定制服务：我司有专业研发团队，可提供杂质定制服务，以大可能的满足您对杂质对照品的选购需求。

利格列汀杂质对照品结构确证

中文名称	英文名称
利格列汀标准品	Linagliptin
利格列汀杂质1	2-((R)-3-aminopiperidine-1-carbonyl)-N-((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)benzamide
利格列汀杂质2	(R)-7-(but-2-yn-1-yl)-8-(3-(1,3-dioxoisoindolin-2-yl)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
利格列汀杂质3	N-Phthalimide-linagliptin
利格列汀杂质4	N1,N2-bis((R)-1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)phthalamide
利格列汀杂质5	(R)-2-((1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamoyl)benzoic acid
利格列汀杂质6	8-((R)-3-aminopiperidin-1-yl)-7-((R)-buta-1,2-dien-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione compound with 8-((R)-3-aminopiperidin-1-yl)-7-((S)-buta-1,2-dien-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione (1:1)
利格列汀杂质7	Linagliptin Diene Impurity
利格列汀杂质8	Linagliptin Acetamide
利格列汀杂质9	(R)-tert-butyl (1-(1,7-di(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate
利格列汀杂质10	(R)-8-(3-aminopiperidin-1-yl)-1,7-di(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione
利格列汀杂质11	8-bromo-3-methyl-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
利格列汀杂质12	(R)-tert-butyl (1-(3-methyl-7-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate
利格列汀杂质13	(R)-8-(3-aminopiperidin-1-yl)-3-methyl-7-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
利格列汀杂质14	(R)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-8-(piperidin-3-ylamino)-1H-purine-2,6(3H,7H)-dione
利格列汀杂质15	(R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)-2,2,2-trifluoroacetamide
利格列汀杂质16	(S)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
利格列汀杂质17	(S)-Linagliptin
利格列汀杂质18	N-(2-acetylphenyl)-2-(8-bromo-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide
利格列汀杂质19	(R)-tert-butyl (1-(1-(2-((2-acetylphenyl)amino)-2-oxoethyl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate
利格列汀杂质20	(R)-N-(2-acetylphenyl)-2-(8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)acetamide
利格列汀杂质21	(R)-tert-butyl (1-(7-(but-2-yn-1-yl)-3-methyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate
利格列汀杂质22	(R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione
利格列汀杂质23	(S)-tert-butyl (1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)carbamate
利格列汀杂质24	(R)-7-(but-2-yn-1-yl)-8-(3-((7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)amino)piperidin-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione
利格列汀杂质25	(R)-N-(1-(7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)formamide

糖尿病是当前威胁人类健康的重要慢性疾病之一。根据糖尿病联盟(IDF)统计，我国糖尿病患者人数高达9860万，居球*。我国2型糖尿病领域呈现“三高一低”现状，即老年人糖尿病患病率高、肝肾功能受损患者比例高、合并多种疾病及联合用药比例较高，血糖控制达标率低，这些特点导致我国糖尿病的临床治疗需求复杂。在选择糖尿病治疗药物时，除关注降糖疗效外，还要重视药物的低血糖风险、药物相互作用、肝肾安全性及用药依从性等问题。

利格列汀杂质对照品结构确证

留言框

产品：

您的单位：

您的姓名：

联系电话：

常用邮箱：

省份：

详细地址：

补充说明：

验证码：

利格列汀杂质对照品 结构确证

留言框

产品：